Highest-materiality recent filing
BioNexus begins VitaGuard MRD deployment in Southeast Asia; aims to undercut $3,000 legacy tests
Initial deployments in select Southeast Asian medical hubs during 2026; platform targets under $3,000 per test vs legacy costs often exceeding $3,000.
ARC Group committed to buy up to $500M of BGLC common stock over 36 months at 3.0-3.5% discount to VWAP; 175k commitment shares issued at $4.32.
BGLC enters definitive cross-equity deal for Fidelion's VitaGuard MRD platform in SE Asia
BGLC subscribes for at least 15% of Fidelion shares; issues 19.9% of its common stock to Fidelion.
BioNexus Gene Lab signs non-binding partnership with BirchBioMed for FS2 topical platform in SE Asia
BGLC to lead Birch's $10M financing round; will issue 4.99% of its outstanding common shares to Birch.
BioNexus Gene Lab enters strategic alliance for VitaGuard MRD platform in SE Asia
BGLC to acquire equity stake in Fidelion Diagnostics and exclusive commercial rights to VitaGuard MRD platform across ASEAN.
Concurrent with the new appointment, Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.
On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately.
Max materiality 0.75 · Median 0.50 · Most common event other_material